Abstracts tagged "rituximab and tocilizumab"

Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Daniela Santos Faria¹, Mónica Eusébio², Joana Leite Silva³, Joana Ramos Rodrigues¹, Joana Sousa Neves¹, Ana Catarina Duarte⁴, Carina Lopes⁵, Ana Valido⁶, Joana Dinis⁶, João Freitas⁷, Mariana Santiago⁷, Raquel Ferreira⁸, Sara Ganhão⁹, Luís Cunha Miranda¹⁰, Daniela Peixoto¹, Filipa Teixeira¹, Sérgio Alcino¹, Carmo Afonso¹, José Tavares Costa³ and Maria José Santos¹¹, ¹Rheumatology, ULSAM, Ponte de Lima, Portugal, ²Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ³Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁷Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, ⁸Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁹Rheumatology, Centro Hospitalar de São João, Porto, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…
Abstract Number: 1614 • 2016 ACR/ARHP Annual Meeting
Monotherapy with Abatacept, Rituximab or Tocilizumab Is Not Associated with a Significantly Lower Long Term Retention Than Combination with Synthetic DMARD: Long-Term Registry Data in 4498 Real-Life Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq¹³, Elodie Perrodeau¹⁴, Philippe Ravaud¹⁵, Xavier Mariette¹⁶ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁵Epidemiologist, PARIS, France, ¹⁶Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Data are very limited concerning the association between cotreatment with a conventional synthetic DMARD (csDMARD) and long term retention of abatacept (ABA), rituximab (RTX) and tocilizumab…
Abstract Number: 1998 • 2016 ACR/ARHP Annual Meeting
Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq^13,14, Elodie Perrodeau¹⁵, Philippe Ravaud¹⁶, Xavier Mariette¹⁷ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Rheumatology, Rouen University Hospital, Rouen, France, ¹⁵Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁶Epidemiologist, PARIS, France, ¹⁷Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Three non-TNF targeted biologics – rituximab, abatacept, and tocilizumab – are widely used, notably in TNF-IR patients. We aimed to compare the efficacy and safety…
Abstract Number: 2613 • 2016 ACR/ARHP Annual Meeting
Seropositivity for RF or ACPA Predicts Long Term Drug Retention with Rituximab, but Not with Abatacept and Tocilizumab : Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq¹³, Elodie Perrodeau¹⁴, Philippe Ravaud¹⁵, Xavier Mariette¹⁶ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁵Epidemiologist, PARIS, France, ¹⁶Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Seropositivity for RF or ACPA is associated with a better short-term effectiveness and drug retention of abatacept (ABA) and rituximab (RTX). Data are very…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…
Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting
First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Tristan Pascart¹, Rene-Marc Flipo², Xavier Deprez³ and Eric Houvenagel⁴, ¹Rheumatology, Saint-Philibert Hospital, Lille, France, ²Rheumatology, University Hospital Lille, Lille, France, ³Rhumatologie, Ch De Valenciennes, Valenciennes, France, ⁴Rheumatology, Saint-Philibert Hospital, LOMME, France
Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting
Rituximab Done! What’s Next in RA?
Ulrich A. Walker¹, Veronika K. Jaeger¹, Katerina Chatzidionysiou², Merete Lund Hetland^3,4, Ellen Margrethe Hauge^3,4, Karel Pavelka⁵, Dan C. Nordström⁶, Helena Canhao⁷, Matija Tomsic⁸, Ronald van Vollenhoven² and Cem Gabay⁹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ²Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁴DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁵Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, Helsinki, Finland, ⁷Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal on behalf of the Rheumatic Diseases Portugal Register, Lisbon, Portugal, ⁸Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, ⁹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland
Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…
Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting
Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…
Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Lillian J. Barra¹, Andrew Ha², Louise Sun³, Catarina Fonseca⁴ and Janet E. Pope⁵, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²The University of Toronto, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Universidade de Lisboa, Lisbon, Portugal, ⁵Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].